Kuno van der Post Ph.D
OmniComm Systems, Inc.
Companies Form Strategic Partnership to Revolutionize Phase I Clinic Process Workflow
Fort Lauderdale, FL, March 2, 2011 - OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne suite of applications has been chosen by West Coast Clinical Trials (WCCT) to automate their clinical trial operations and processes within their early-phase clinics. The selection of TrialOne by WCCT ends an exhaustive search to find technologies that are specifically designed to handle the unique processes and workflows within their high-paced clinic.
"Working in the clinical trials space for over 13 years, you come across many platforms and systems that say they speak to the needs of the early phase clinical trial environment, said Jon Rojas, Chief Operating Officer at WCCT." Rojas added, "I had yet to see one that addressed all those needs until TrialOne. Though it took us over a year to come to this decision, it will be time well spent having done our due diligence to have a system that helps increase data quality, decrease costs and better meet the high demands of early phase development."
TrialOne is a web-based, mobile, clinic automation solution designed specifically for early-phase research to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne offers time-based data entry and integration with bar-code scanners and printers and biomedical monitoring devices to automate data, sample collection and processing. The flexible and configurable workflow streamlines operational and data management processes, while enhancing protocol compliance and data quality.
"We are extremely pleased to be chosen by WCCT to assist them with their clinical research needs," said Stephen Johnson, President and COO of OmniComm. "WCCT has built up an excellent reputation in Phase I over the past ten years and has conducted hundreds of clinical studies involving thousands of volunteers for nationally and internationally recognized pharmaceutical and biotechnology companies. We are delighted to be partnering with them to offer solutions that will help them continue to improve their service offering." WCCT and OmniComm have also agreed to a partnership and will collaborate on future development plans for the TrialOne suite.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
About West Coast Clinical Trials
WCCT is a privately owned independent Phase I-IV CRO, conveniently located near 3 major airports in Southern California. WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Asthma. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. Our location and access to an ethnically diverse population allows us to conduct a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 40,000 square feet, a well-trained and experienced staff, and advanced technological procedures, we bring the highest quality to the pharmaceutical and biotechnology industries.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.